These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

641 related articles for article (PubMed ID: 31423712)

  • 1. Safety, Tolerability and efficacy of Rapid Optimization, helped by NT-proBNP and GDF-15, of Heart Failure therapies (STRONG-HF): rationale and design for a multicentre, randomized, parallel-group study.
    Kimmoun A; Cotter G; Davison B; Takagi K; Addad F; Celutkiene J; Chioncel O; Solal AC; Diaz R; Damasceno A; Duengen HD; Filippatos G; Goncalvesova E; Merai I; Metra M; Ponikowski P; Privalov D; Sliwa K; Sani MU; Voors AA; Shogenov Z; Mebazaa A
    Eur J Heart Fail; 2019 Nov; 21(11):1459-1467. PubMed ID: 31423712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.
    Martin N; Manoharan K; Davies C; Lumbers RT
    Cochrane Database Syst Rev; 2021 May; 5(5):CD012721. PubMed ID: 34022072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.
    Martin N; Manoharan K; Thomas J; Davies C; Lumbers RT
    Cochrane Database Syst Rev; 2018 Jun; 6(6):CD012721. PubMed ID: 29952095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of Limitations to Optimization of Guideline-Directed Medical Therapy in Heart Failure From the GUIDE-IT Trial: A Secondary Analysis of a Randomized Clinical Trial.
    Fiuzat M; Ezekowitz J; Alemayehu W; Westerhout CM; Sbolli M; Cani D; Whellan DJ; Ahmad T; Adams K; Piña IL; Patel CB; Anstrom KJ; Cooper LS; Mark D; Leifer ES; Felker GM; Januzzi JL; O'Connor CM
    JAMA Cardiol; 2020 Jul; 5(7):757-764. PubMed ID: 32319999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of heart failure pharmacotherapies in patients with heart failure with mildly reduced ejection fraction.
    Schupp T; Bertsch T; Reinhardt M; Abel N; Schmitt A; Lau F; Abumayyaleh M; Akin M; Weiß C; Weidner K; Behnes M; Akin I
    Eur J Prev Cardiol; 2024 Aug; 31(11):1347-1360. PubMed ID: 38513366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial.
    Mebazaa A; Davison B; Chioncel O; Cohen-Solal A; Diaz R; Filippatos G; Metra M; Ponikowski P; Sliwa K; Voors AA; Edwards C; Novosadova M; Takagi K; Damasceno A; Saidu H; Gayat E; Pang PS; Celutkiene J; Cotter G
    Lancet; 2022 Dec; 400(10367):1938-1952. PubMed ID: 36356631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term results of intensified, N-terminal-pro-B-type natriuretic peptide-guided versus symptom-guided treatment in elderly patients with heart failure: five-year follow-up from TIME-CHF.
    Sanders-van Wijk S; Maeder MT; Nietlispach F; Rickli H; Estlinbaum W; Erne P; Rickenbacher P; Peter M; Pfisterer MP; Brunner-La Rocca HP;
    Circ Heart Fail; 2014 Jan; 7(1):131-9. PubMed ID: 24352403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Guideline-directed medical therapy in severe heart failure with reduced ejection fraction: An analysis from the HELP-HF registry.
    Tomasoni D; Pagnesi M; Colombo G; Chiarito M; Stolfo D; Baldetti L; Lombardi CM; Adamo M; Maggi G; Inciardi RM; Loiacono F; Maccallini M; Villaschi A; Gasparini G; Montella M; Contessi S; Cocianni D; Perotto M; Barone G; Merlo M; Cappelletti AM; Rosano G; Sinagra G; Pini D; Savarese G; Metra M
    Eur J Heart Fail; 2024 Feb; 26(2):327-337. PubMed ID: 37933210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationale and design of the GUIDE-IT study: Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure.
    Felker GM; Ahmad T; Anstrom KJ; Adams KF; Cooper LS; Ezekowitz JA; Fiuzat M; Houston-Miller N; Januzzi JL; Leifer ES; Mark DB; Desvigne-Nickens P; Paynter G; Piña IL; Whellan DJ; O'Connor CM
    JACC Heart Fail; 2014 Oct; 2(5):457-65. PubMed ID: 25194287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-World Analysis of Guideline-Based Therapy After Hospitalization for Heart Failure.
    Wirtz HS; Sheer R; Honarpour N; Casebeer AW; Simmons JD; Kurtz CE; Pasquale MK; Globe G
    J Am Heart Assoc; 2020 Aug; 9(16):e015042. PubMed ID: 32805181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences in NT-proBNP Response and Prognosis in Men and Women With Heart Failure With Reduced Ejection Fraction.
    Daubert MA; Yow E; Barnhart HX; Piña IL; Ahmad T; Leifer E; Cooper L; Desvigne-Nickens P; Fiuzat M; Adams K; Ezekowitz J; Whellan DJ; Januzzi JL; O'Connor CM; Felker GM
    J Am Heart Assoc; 2021 May; 10(10):e019712. PubMed ID: 33955231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting N-Terminal Pro-Brain Natriuretic Peptide in Older Versus Younger Acute Decompensated Heart Failure Patients.
    Stienen S; Salah K; Eurlings LW; Bettencourt P; Pimenta JM; Metra M; Bayes-Genis A; Verdiani V; Bettari L; Lazzarini V; Tijssen JP; Pinto YM; Kok WE
    JACC Heart Fail; 2016 Sep; 4(9):736-45. PubMed ID: 27395353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Efficacy of Traditional Heart Failure Therapies in Patients With Cardiac Amyloidosis and Heart Failure.
    Yan CL; Gallo RA; Vasquez Martinez M; Rivera Rodriguez B; Trujillo L; Thakkar Rivera N; Hoffman JE
    Am J Cardiol; 2023 Oct; 204():360-365. PubMed ID: 37573615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Importance of Worsening Heart Failure in Ambulatory Patients: Definition, Characteristics, and Effects of Amino-Terminal Pro-B-Type Natriuretic Peptide Guided Therapy.
    Mallick A; Gandhi PU; Gaggin HK; Ibrahim N; Januzzi JL
    JACC Heart Fail; 2016 Sep; 4(9):749-55. PubMed ID: 27179830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study.
    Teng TK; Tromp J; Tay WT; Anand I; Ouwerkerk W; Chopra V; Wander GS; Yap JJ; MacDonald MR; Xu CF; Chia YM; Shimizu W; ; Richards AM; Voors A; Lam CS
    Lancet Glob Health; 2018 Sep; 6(9):e1008-e1018. PubMed ID: 30103979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperkalemia and Treatment With RAAS Inhibitors During Acute Heart Failure Hospitalizations and Their Association With Mortality.
    Beusekamp JC; Tromp J; Cleland JGF; Givertz MM; Metra M; O'Connor CM; Teerlink JR; Ponikowski P; Ouwerkerk W; van Veldhuisen DJ; Voors AA; van der Meer P
    JACC Heart Fail; 2019 Nov; 7(11):970-979. PubMed ID: 31606364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment Patterns, Outcomes, and Persistence to Newly Started Heart Failure Medications in Patients with Worsening Heart Failure: A Cohort Study from the United States and Germany.
    Michel A; Lecomte C; Ohlmeier C; Raad H; Basedow F; Haeckl D; Beier D; Evers T
    Am J Cardiovasc Drugs; 2024 May; 24(3):409-418. PubMed ID: 38573461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modern heart failure treatment is superior to conventional treatment across the left ventricular ejection spectrum: real-life data from the Swedish Heart Failure Registry 2013-2020.
    Karlström P; Pivodic A; Dahlström U; Fu M
    Clin Res Cardiol; 2024 Sep; 113(9):1355-1368. PubMed ID: 39186181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurohumoral effects of aliskiren in patients with symptomatic heart failure receiving a mineralocorticoid receptor antagonist: the Aliskiren Observation of Heart Failure Treatment study.
    Pitt B; Latini R; Maggioni AP; Solomon SD; Smith BA; Wright M; Prescott MF; McMurray JJ
    Eur J Heart Fail; 2011 Jul; 13(7):755-64. PubMed ID: 21467028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variation in use and dosing escalation of renin angiotensin system, mineralocorticoid receptor antagonist, angiotensin receptor neprilysin inhibitor and beta-blocker therapies in heart failure and reduced ejection fraction: Association of comorbidities.
    Albert NM; Tyson RJ; Hill CL; DeVore AD; Spertus JA; Duffy C; Butler J; Patterson JH; Hernandez AF; Williams FB; Thomas L; Fonarow GC
    Am Heart J; 2021 May; 235():82-96. PubMed ID: 33497697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.